L3VLUP
ProSign in

ARWR · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ARWRVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ARWR
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterARWRVRTX
Q3 20204 holders, $221m31 holders, $21.9bn
Q4 20205 holders, $372m30 holders, $18.4bn
Q1 20215 holders, $336m31 holders, $15.4bn
Q2 20216 holders, $253m30 holders, $12.7bn
Q3 20215 holders, $133m35 holders, $10.1bn
Q4 20213 holders, $249m28 holders, $12.4bn
Q1 20225 holders, $161m23 holders, $16.1bn
Q2 20223 holders, $122m25 holders, $18.1bn
Q3 20223 holders, $118m22 holders, $18.4bn
Q4 20222 holders, $121m28 holders, $18.4bn
Q1 20234 holders, $69m26 holders, $21.4bn
Q2 20234 holders, $67m27 holders, $24.7bn
Q3 20233 holders, $62m33 holders, $24.3bn
Q4 20234 holders, $87m32 holders, $28.6bn
Q1 20244 holders, $67m31 holders, $29.8bn
Q2 20244 holders, $61m29 holders, $33.4bn
Q3 20243 holders, $29m27 holders, $33.5bn
Q4 20243 holders, $40m26 holders, $28.5bn
Q1 20252 holders, $7.4m21 holders, $35.4bn
Q2 20255 holders, $56m21 holders, $32.3bn
Q3 202510 holders, $232m22 holders, $25.9bn
Q4 20256 holders, $275m26 holders, $31.8bn
Q1 20268 holders, $257m25 holders, $31.8bn
Q2 20269 holders, $969m26 holders, $34.6bn
ARWR

Arrowhead Pharmaceuticals In

Holders
4
Reported value
$61m
Buyers
2
Sellers
2

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
29
Reported value
$33.4bn
Buyers
12
Sellers
18

Breadth -6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ARWR (2)

Rokos Capital Management LLP, Woodline Partners LP

Only VRTX (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →